Abstract
Secondary therapy-related, acute lymphoblastic leukemia (S-ALL) is less common than its myeloblastic counterpart. S-ALL with MLL gene rearrangements have only been reported on six previous occasions. Only three of these had t(4;11)(q21;23) S-ALL with MLL-AF4 fusion transcript has only been reported in one earlier case. In this report a rare case of S-ALL with MLL-AF4 transcript is described in a 36 year old woman treated for breast carcinoma with chemotherapy which included the topoisomerase II inhibitor, VP-16. The precise incidence of MLL gene rearrangement in S-ALL still remains to be clarified.
MeSH terms
-
Adult
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Chromosomes, Human, Pair 11
-
DNA-Binding Proteins / genetics*
-
Drug Resistance, Neoplasm
-
Etoposide / therapeutic use
-
Female
-
Gene Rearrangement
-
Histone-Lysine N-Methyltransferase
-
Humans
-
Myeloid-Lymphoid Leukemia Protein
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
Proto-Oncogenes*
-
Recurrence
-
Remission Induction
-
Topoisomerase II Inhibitors*
-
Transcription Factors*
-
Translocation, Genetic*
Substances
-
Antineoplastic Agents, Phytogenic
-
DNA-Binding Proteins
-
KMT2A protein, human
-
Topoisomerase II Inhibitors
-
Transcription Factors
-
Myeloid-Lymphoid Leukemia Protein
-
Etoposide
-
Histone-Lysine N-Methyltransferase